MannKind Co. (NASDAQ:MNKD) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 34,425,319 shares, an increase of 4.4% from the January 12th total of 32,969,296 shares. Based on an average daily trading volume, of 8,223,627 shares, the days-to-cover ratio is currently 4.2 days. Approximately 34.5% of the shares of the stock are short sold.

Several research analysts have recently weighed in on the company. Maxim Group reaffirmed a “hold” rating on shares of MannKind in a research note on Tuesday, January 30th. S&P Equity Research reduced their price objective on MannKind from $3.49 to $2.77 in a research note on Thursday, January 25th. Zacks Investment Research raised MannKind from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. BidaskClub downgraded MannKind from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, ValuEngine raised MannKind from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $1.89.

MannKind (NASDAQ MNKD) traded up $0.05 during midday trading on Friday, reaching $2.61. The company had a trading volume of 2,617,754 shares, compared to its average volume of 4,757,837. MannKind has a 1 year low of $0.67 and a 1 year high of $6.96. The company has a current ratio of 0.31, a quick ratio of 0.28 and a debt-to-equity ratio of -0.43. The firm has a market cap of $287.18, a P/E ratio of -9.59 and a beta of 3.18.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.11). MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The firm had revenue of $2.04 million during the quarter, compared to analyst estimates of $2.56 million. During the same period in the prior year, the company posted $1.30 earnings per share. The firm’s revenue for the quarter was down 98.7% compared to the same quarter last year. research analysts predict that MannKind will post -1.13 EPS for the current fiscal year.

In other MannKind news, VP Stuart A. Tross bought 39,840 shares of MannKind stock in a transaction dated Thursday, December 21st. The stock was acquired at an average cost of $2.52 per share, with a total value of $100,396.80. Following the purchase, the vice president now directly owns 59,840 shares in the company, valued at approximately $150,796.80. The acquisition was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in MannKind by 82.8% in the 4th quarter. BlackRock Inc. now owns 3,534,811 shares of the biopharmaceutical company’s stock valued at $8,201,000 after purchasing an additional 1,600,802 shares during the last quarter. Balyasny Asset Management LLC acquired a new position in MannKind in the 2nd quarter valued at $568,000. Dupont Capital Management Corp raised its stake in MannKind by 99.9% in the 4th quarter. Dupont Capital Management Corp now owns 201,900 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 100,900 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in MannKind by 60.5% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 188,428 shares of the biopharmaceutical company’s stock valued at $438,000 after purchasing an additional 71,012 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in MannKind by 63.3% in the 4th quarter. Wells Fargo & Company MN now owns 146,916 shares of the biopharmaceutical company’s stock valued at $340,000 after purchasing an additional 56,965 shares during the last quarter. 12.25% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “MannKind Co. (MNKD) Short Interest Up 4.4% in January” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2018/02/09/mannkind-co-mnkd-short-interest-up-4-4-in-january.html.

About MannKind

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.